Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01626
|
|||||
| Drug Name |
Genz 644282
|
|||||
| Synonyms |
GENZ-644282; Genz 644282; genz644282; UNII-717I541I2R; 717I541I2R; 2,3-dimethoxy-12-(2-(methylamino)ethyl)-[1,3]dioxolo[4',5':4,5]benzo[1,2-h]benzo[c][1,6]naphthyridin-13(12H)-one; SCHEMBL241696; CHEMBL191958; EX-A481; AOB87160; BCP20983; ZINC6718458; SAR402674; AKOS030526835; CS-1525; SAR 402674; SAR-402674; HY-16228; Benzo(C)(1,3)benzodioxolo(5,6-H)(1,6)naphthyridin-13(12H)-one, 2,3-dimethoxy-12-(2-(methylamino)ethyl)-; BC600645; DA-42192; GENZ-644282/GENZ644282; FT-0700324; A3434; W-6112; A13206
|
|||||
| Indication | Solid tumours [ICD11: 2D4Z] | Phase 1 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H21N3O5
|
|||||
| Canonical SMILES |
CNCCN1C2=C(C=NC3=CC4=C(C=C32)OCO4)C5=CC(=C(C=C5C1=O)OC)OC
|
|||||
| InChI |
InChI=1S/C22H21N3O5/c1-23-4-5-25-21-14-8-19-20(30-11-29-19)9-16(14)24-10-15(21)12-6-17(27-2)18(28-3)7-13(12)22(25)26/h6-10,23H,4-5,11H2,1-3H3
|
|||||
| InChIKey |
BAORCAMWLWRZQG-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 529488-28-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 407.4 | Topological Polar Surface Area | 82.2 | ||
| Heavy Atom Count | 30 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2.2
|
|||||
| PubChem CID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00942799) Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors | |||||
| 2 | Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011 Aug;10(8):1490-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.